-transparent.png){kind=logo}
A double-blind clinical trial of zimeldine, a potent inhibitor of central serotonin reuptake, versus imipramine and placebo was carried out on 44 patients suffering from agoraphobia with panic attacks. Zimeldine was a superior treatment on all rating scales other than a global rating scale which did not reach statistically significant superiority. Imipramine was not shown to be superior to placebo. The implications of these results for further research on the underlying pathophysiology of agoraphobia with panic attacks are discussed.
Related Publications
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
January 1985,
Comprehensive psychiatry,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
January 1996,
Psychopharmacology bulletin,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
January 1988,
Psychopathology,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
January 1983,
Acta psychiatrica Scandinavica. Supplementum,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
May 1988,
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
January 1987,
Biological psychiatry,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
January 1988,
International clinical psychopharmacology,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
January 1987,
International clinical psychopharmacology,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
May 1990,
The Journal of clinical psychiatry,
L Evans, and
J Kenardy, and
P Schneider, and
H Hoey
January 1990,
Current medical research and opinion,
